NCT00223093Unknown1 期
A Single-Center Open-Labelled Study of the Administration of Transplant-Acceptance Inducing Cells (TAIZ) for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)
University Hospital Schleswig-Holstein0 个研究点目标入组 10 人开始时间: 2004年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 主要终点
- graft survival
研究概览
简要总结
Induce tolerance or reduce the amount of immunosuppression after renal transplant patient (receiving cadaver kidney)with so called TAIZ-monocytes
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •4.3.1 Inclusion Criteria
- •Patients must meet all the following inclusion criteria to be considered for admission to the trial:
- •Male or female adult patients aged between 18 and 64 years (inclusive). A female of childbearing potential may be enrolled provided she:
- •has a negative pregnancy test at Screening and
- •is routinely using adequate contraception prior to and during the study and
- •agrees not to attempt to become pregnant during the study and
- •is not lactating A female of non-childbearing potential will be defined as one who has been postmenopausal for at least one year or has been surgically sterilised.
- •Patients receiving a first renal transplant.
- •Patients who fulfil the criteria to receive an allogeneic renal transplant from a cadaver (according to the Eurotransplant (ET) manual on organ allocation and the Bundesärztekammer allocation criteria).
- •Patients who, after the nature of the study and the disclosure of their data has been explained to them, have freely given Informed Consent in writing.
排除标准
- •Patients presenting any of the following exclusion criteria must not be included in the trial:
- •Patients who have received a renal transplant.
- •Patients who have an active infection at the time of entry into the study (Screening).
- •Recipient and donor pairs who show the following incompatible CMV constellation: the donor is CMV positive and the recipient is CMV negative.
- •Patients and donor who have positive evidence of HIV or have active virus hepatitis B and C.
- •Patients with a history of alcohol and/or drug abuse.
- •Patients who are pregnant women or nursing mothers.
- •Known hypersensitivity or contraindication to one of the immunosuppressives administered during the course of the study: tacrolimus, sirolimus or steroids (prednisolone and methylprednisolone).
- •Patients with a history or present symptoms of autoimmune vasculitis.
- •Detection of >5% HLA antibodies (current values determined during the last three months).
- •Patients with a malignancy or history of malignancy.
- •Patients with renal insufficiency due to a vasculitis.
- •Recipient and donor pairs with complete HLA matching.
- •Patients whose condition requires continuous systemic steroid administration.
- •Patients who are simultaneously participating or plan to participate in any other clinical study.
- •Psychiatric or emotional problems or lack of knowledge of the German language which would invalidate the giving of Informed Consent or limit the ability of the subject to comply with study requirements.
- •Unwillingness or inability to provide Informed Consent or to participate satisfactorily for the entire trial period
结局指标
主要结局
graft survival
replacement of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC)
serum creatinine
rejection episodes
re-introduction of immunosuppressives.
次要结局
- safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) Adverse Events (AEs)
研究者
相似试验
Unknown
1 期
Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-MonocytesRenal TransplantationNCT00223067University Hospital Schleswig-Holstein10
已完成
4 期
HARMONY:A triple arm, prospectively randomized, multi-center study phase IV to evaluate calcineurin inhibitor reduced and steroid-free immunosupression in low immunological risk patients.Z94.0Kidney transplant statusDRKS00000452niversitätsklinikum Freiburg631
Unknown
不适用
Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf TestKidney Transplant RejectionImmunosuppressionNCT04670926Transplant Genomics, Inc.75
已完成
2 期
Telmisartan Versus Losartan in Kidney TransplantationRenal TransplantNCT01224860Mario Negri Institute for Pharmacological Research20
Unknown
4 期
CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant RecipientsRenal TransplantNCT00737659Rabin Medical Center138